Cocrystal Pharma Announces $5M Private Placement with OPKO

What Happened

• Cocrystal Pharma, Inc. announced that on July 31, 2026 it entered into a Securities Purchase Agreement (SPA) with OPKO Health, Inc., an accredited investor, selling 5,474,053 shares of common stock for gross proceeds of $5.0 million. The purchase price was $0.9134 per share, equal to the Nasdaq Consolidated Bid Price on the trading day of closing. The SPA is filed as an exhibit to the Form 8-K. OPKO’s chairman and CEO, Dr. Phillip Frost, is a co‑founder, director and principal stockholder of Cocrystal.

Key Details

• Shares sold: 5,474,053 common shares
• Price per share: $0.9134 (Nasdaq Consolidated Bid Price on closing day)
• Gross proceeds: $5.0 million
• Transaction date: July 31, 2026; press release issued August 3, 2026
• Purchaser: OPKO Health, Inc.; note that Dr. Phillip Frost is both OPKO’s CEO and a Cocrystal co‑founder/director/principal stockholder
• Use of proceeds: advance preclinical and clinical programs, general corporate purposes and working capital
• Form of SPA included as Exhibit 10.1 to the 8-K

Why It Matters

• The company raised $5.0M to fund R&D and operations, which supports ongoing preclinical and clinical programs.
• The investor is affiliated through Dr. Phillip Frost, so this is a related-party/private placement that investors should note when assessing governance and potential conflicts.
• The issuance increases the company’s outstanding shares by 5.47M, which is dilutionary to existing shareholders; investors should consider the impact on share count and per‑share metrics.